| Code | CSB-RA006147MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to SHR-1906, designed to specifically target CCN2 (Connective Tissue Growth Factor, CTGF). CCN2 is a matricellular protein that plays a critical role in regulating extracellular matrix production, tissue remodeling, and fibrotic processes. It functions as a downstream mediator of transforming growth factor-beta (TGF-β) signaling and is involved in cellular adhesion, migration, proliferation, and differentiation. Elevated CCN2 expression is associated with various fibrotic diseases affecting the kidney, liver, lung, and skin, as well as certain cancers where it contributes to tumor progression, angiogenesis, and metastasis.
SHR-1906 is a therapeutic antibody candidate developed for the treatment of fibrotic disorders, particularly idiopathic pulmonary fibrosis and other conditions characterized by excessive tissue scarring. This biosimilar provides researchers with a valuable tool for investigating CCN2-mediated pathways in fibrogenesis, wound healing, and disease pathology. It enables studies exploring the therapeutic potential of CCN2 inhibition and facilitates the development of novel interventions targeting fibrotic and proliferative disorders.
There are currently no reviews for this product.